Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?
In this issue of ESMO Open, Hurvitz and colleagues1 report an exploratory analysis of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in the subgroup of 82 patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and baseline brain metastases (BrMs) from the landmark DESTINY-Breast03 clinical trial. Impressively, the intracranial response rate (i-ORR) was 65.7% with T-DXd versus 34.3% with T-DM1 confirming antibody–drug conjugates (ADCs) as a promising strategy in treating breast cancer BrMs.
